“Commercializing Vaccines, Anti-Infectives, and Diagnostics that Address Human Microbial Threats.”
Dr. Robert Hopkins is a visionary physician-executive and thought leader whose career has been defined by an unwavering commitment to combating infectious diseases through science, innovation, and leadership. With over three decades of experience across regulatory, clinical, and product development disciplines, Dr. Hopkins has established himself as a trusted authority in vaccine and anti-infective development, guiding both emerging biotech ventures and global pharmaceutical enterprises toward transformative public health outcomes. His professional journey reflects a rare fusion of medical rigor, regulatory expertise, and entrepreneurial acumen, grounded in an enduring belief that scientific advancement must serve humanity.
Born with an inquisitive mind and an early fascination with biology, Dr. Hopkins pursued his Bachelor of Science in Biology at Lewis and Clark College, graduating magna cum laude. His intellectual curiosity and passion for global health led him to Tulane University, where he simultaneously earned his Doctor of Medicine (MD) and his Master of Public Health and Tropical Medicine (MPH & TM). These formative years shaped not only his technical mastery but also his worldview—melding a clinician’s empathy with a public health professional’s strategic vision. He later completed his internship at Emory University, followed by residency and fellowship training in Internal Medicine and Infectious Diseases at the University of Maryland School of Medicine. There, he also advanced his research at the Center for Vaccine Development, focusing on the pathogenesis and epidemiology of Helicobacter pylori, setting the stage for a lifetime devoted to microbial and vaccine research.
Dr. Hopkins began his distinguished career at the U.S. Food and Drug Administration (FDA), where he served as Medical Officer and later as Medical Team Leader within the Divisions of Anti-Infective and Special Pathogen Drug Products. His tenure at the FDA was instrumental in shaping the modern regulatory frameworks for anti-infective therapies and vaccine approvals. Over the course of six years, he led pivotal reviews for antibiotics, antivirals, antiparasitics, and vaccines, including landmark submissions for ciprofloxacin, moxifloxacin, and Levofloxacin (Levaquin®). His leadership and technical insight directly influenced FDA guidance on Helicobacter pylori drug development, harmonizing international clinical trial standards.
Following his government service, Dr. Hopkins transitioned into industry, taking his deep regulatory insight to the frontlines of innovation. As Director of Infectious Diseases at Merck Research Laboratories, he guided multinational clinical trials supporting supplemental indications for Cancidas® (caspofungin acetate)—an antifungal agent used in immunocompromised populations. His work bridged science and strategy, ensuring that complex therapies met both the highest regulatory standards and the most urgent patient needs. This role marked the beginning of his career-long ability to unite government, academia, and industry in pursuit of medical breakthroughs.
In the years that followed, Dr. Hopkins assumed increasingly senior roles within organizations at the forefront of biodefense, vaccine, and anti-infective development. As Director and later Vice President of Clinical Research at DynPort Vaccine Company, he oversaw the design and execution of clinical trials for critical biodefense products including smallpox, botulinum, and Venezuelan equine encephalitis vaccines. His leadership ensured these complex programs advanced efficiently from laboratory to clinical readiness, strengthening U.S. national preparedness against biological threats.
During his 13-year tenure at Emergent BioSolutions, Dr. Hopkins rose to Senior Director of Clinical Development, where he led global clinical and regulatory efforts for vaccines and countermeasures developed under the FDA’s “Animal Rule.” His contributions to BioThrax® (Anthrax Vaccine Adsorbed) and related products were instrumental in establishing Emergent as a leading biodefense innovator. He played an integral role in securing and managing over $1 billion in U.S. government contracts for advanced vaccine development, while also representing the company on critical public health advisory committees, including the Advisory Committee on Immunization Practices (ACIP) and NIH study sections.
Dr. Hopkins’ expertise later guided the Aeras Global TB Vaccine Foundation as Vice President of Product and Clinical Development, where he led multi-national tuberculosis vaccine trials and regulatory submissions supported by the Bill & Melinda Gates Foundation. His work at Aeras reflected both his scientific leadership and his humanitarian ethos—applying the same rigor and precision he brought to biodefense to the global fight against tuberculosis, one of humanity’s oldest infectious diseases.
In 2018, Dr. Hopkins was appointed Senior Medical Advisor at the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services. There, he oversaw the clinical review of vaccines, anti-infectives, diagnostics, and chemical and radiologic countermeasures critical to national health security. His leadership earned multiple Excellence Awards from BARDA, recognizing his capacity to navigate high-stakes challenges where medicine, policy, and emergency response converge.
As Chief Medical Officer at Adaptive Phage Therapeutics (APT) and later at Ocugen Inc., Dr. Hopkins led development teams pioneering new frontiers in bacteriophage therapy, gene and cell therapy, ophthalmologic biologics, and mucosal vaccines. Under his leadership, APT achieved the first-ever FDA-approved placebo-controlled randomized trial demonstrating efficacy with bacteriophage therapy—an achievement heralded as a milestone in antimicrobial resistance research. At Ocugen, he advanced gene therapy and vaccine programs through clinical milestones and federal partnerships, including an NIAID-funded initiative for next-generation mucosal COVID-19 and influenza vaccines.
Today, Dr. Hopkins serves as President of HopkinsClinical LLC, a consultancy providing clinical development, regulatory strategy, and medical affairs support to biopharmaceutical companies from IND-enabling studies to licensure. He also serves as fractional Chief Medical Officer for Nanobiofab and TolkaAI, two innovative biotechnology firms leveraging artificial intelligence and nanosensor technologies to address pathogen detection, wound care, and phage therapy. His career embodies a lifelong dedication to translating discovery into access—ensuring scientific progress tangibly benefits patients and societies worldwide.
Beyond his technical excellence, Dr. Hopkins is recognized for his mentorship, service, and integrity. Board-certified in both Internal Medicine and Infectious Disease, and licensed in Maryland and California, he continues to practice medicine in volunteer and locum tenens roles, reaffirming his belief that leadership in health must remain grounded in direct patient care. His personal interests—woodworking, skiing, and backpacking—reflect the same balance of precision, focus, and adventure that defines his professional path.
Character:
Dr. Hopkins exemplifies integrity, humility, and dedication. He approaches each challenge with a service mindset, balancing scientific precision with compassion for patients and colleagues alike. His decisions are guided by ethical clarity and a genuine belief that leadership means stewardship.
Knowledge:
A scholar-practitioner, Dr. Hopkins combines deep clinical insight with regulatory and scientific expertise spanning over 30 years. His command of infectious disease biology, vaccine science, and product development strategy has shaped major advancements across government and industry. He continues to contribute thought leadership through NIH panels, journal reviews, and public speaking engagements worldwide.
Strategic:
Dr. Hopkins brings an exceptional ability to synthesize complex medical, regulatory, and business dimensions into coherent strategy. His foresight in emerging health threats and innovation pathways has enabled organizations to anticipate trends, secure funding, and deliver high-impact results. His leadership consistently transforms vision into measurable outcomes.
Communication:
Articulate and collaborative, Dr. Hopkins bridges disciplines with clarity and purpose. Whether addressing a boardroom, regulatory body, or global scientific forum, he communicates with precision and authenticity. His ability to connect across cultures and expertise levels makes him both an influential leader and an inspiring mentor.
